Neurogenic

Neurogenic

Neurogenic is a clinical-stage diagnostics company advancing the development of a novel ELISA-based immunoassay to detect pathological Platelet-Associated Antibodies (PAA) in the sera of adolescent and pediatric patients to facilitate the diagnosis of early-onset schizophrenia.

Neurogenic's proprietary reagents and diagnostic assay are protected by a series of worldwide issued patents and pending patent applications.

The company is conducting a clinical trial entitled Collection and Analysis of Blood Samples from Children and Adolescents Experiencing Initial Symptoms of Acute Mental Illness to Develop an ELISA-based Diagnostic Assay to Aid in the Diagnosis of Schizophrenia in collaboration with Beer Yaakov-Ness Ziona Mental Health Center.

Two analytical versions of the diagnostic assay have been developed, one employing the Horseradish Peroxidase (HRP) detection reagent and the other employing the Protein G detection reagent.

A novel monoclonal antibody control has been produced and integrated into the assay procedure.

The Standard Operating Procedures (SOPs) for the HRP and Protein G assays are now being finalized.

For more information, please contact:

Dr. Yechiel Goldman, Ph.D.

Scientific Writer, Consultant

Bikorei HaKerem Regulatory & Scientific Writing

T: +972-54-200-3128

yechiel@bikorei-hakerem.co.il

 

Mr. Yossi Avnat, M.A.

Director

Neurogenic Ltd.

T: +972-3-510-1992

yossi@wcm.co.il